8,647 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Lingohr Asset Management GmbH

Lingohr Asset Management GmbH acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 8,647 shares of the biopharmaceutical company’s stock, valued at approximately $796,000. Gilead Sciences accounts for about 1.6% of Lingohr Asset Management GmbH’s portfolio, making the stock its 20th biggest position.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GILD. HHM Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares during the period. YANKCOM Partnership acquired a new position in shares of Gilead Sciences in the fourth quarter worth approximately $28,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences in the fourth quarter worth approximately $29,000. Crews Bank & Trust acquired a new position in shares of Gilead Sciences in the fourth quarter worth approximately $31,000. Finally, Stephens Consulting LLC increased its holdings in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 260 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 2.5 %

GILD stock opened at $107.51 on Thursday. The stock’s fifty day simple moving average is $103.00 and its two-hundred day simple moving average is $93.47. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The stock has a market cap of $133.89 billion, a P/E ratio of 290.57, a P/E/G ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.94%. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This represents a 1.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 302,785 shares of company stock valued at $30,503,250 in the last 90 days. Insiders own 0.29% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on GILD. Royal Bank of Canada lifted their target price on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. BMO Capital Markets lifted their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Piper Sandler lifted their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Mizuho lifted their target price on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $104.52.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.